MorphoSys (ETR:MOR) has been assigned a €120.00 ($139.53) price target by equities research analysts at JPMorgan Chase & Co. in a report released on Thursday. The firm presently has a “buy” rating on the stock. JPMorgan Chase & Co.’s price objective points to a potential upside of 25.00% from the stock’s previous close.
MOR has been the subject of a number of other research reports. Commerzbank set a €107.00 ($124.42) price objective on shares of MorphoSys and gave the company a “neutral” rating in a report on Wednesday, August 22nd. Royal Bank of Canada set a €65.00 ($75.58) price target on shares of MorphoSys and gave the company a “sell” rating in a report on Monday, October 1st. Oddo Bhf set a €116.00 ($134.88) price target on shares of MorphoSys and gave the company a “buy” rating in a report on Thursday, November 8th. Independent Research set a €104.00 ($120.93) price target on shares of MorphoSys and gave the company a “neutral” rating in a report on Wednesday, November 28th. Finally, HSBC set a €56.00 ($65.12) price target on shares of MorphoSys and gave the company a “sell” rating in a report on Tuesday, August 14th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. MorphoSys currently has a consensus rating of “Hold” and an average target price of €97.30 ($113.14).
MOR traded down €2.65 ($3.08) on Thursday, reaching €96.00 ($111.63). 128,519 shares of the company traded hands, compared to its average volume of 153,687. MorphoSys has a one year low of €49.63 ($57.71) and a one year high of €88.10 ($102.44).
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Featured Article: Find a Trading Strategy That Works
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.